HK Stock Market Move | SBP GROUP (01177) rises over 6%. TRD205 "AT2R antagonist" has been included in the CDE's breakthrough therapy drug list.

SBP Group (01177) rose more than 6%, at the time of reporting, up by 6.07% to 5.41 Hong Kong dollars, with a turnover of 452 million Hong Kong dollars. On the news front, SBP Group announced that its subsidiary, Beijing Ted Pharmaceutical Co., Ltd. ("Beijing Ted"), has completed Phase II clinical trials for the national Class 1 new drug TRD205, an "AT2R antagonist" developed independently by Beijing Ted for chronic postoperative neuropathic pain (CPSNP). Based on the positive results of the trial, TRD205 has been included in the list of breakthrough therapeutic drugs by China's National Medical Products Administration Drug Evaluation Center (CDE). The inclusion of TRD205 as a breakthrough therapeutic drug this time is mainly based on a multicenter, randomized, double-blind, placebo-controlled, dose-exploration Phase II clinical trial, aimed at evaluating its effectiveness and safety in the treatment of chronic postoperative neuropathic pain. As one of the representative achievements of the group's second-generation AI drug discovery platform transformation, TRD205 further validates the practical application value of AI technology in molecular structure generation and candidate screening. The group will continue to advance the subsequent clinical development of TRD205 and expand its exploration in other chronic pain indications such as diabetic peripheral neuropathic pain (DPNP) to provide new solutions for the treatment of chronic neuropathic pain.